Assessing Harms When Comparing Medical Interventions
暂无分享,去创建一个
T. Wilt | P. Santaguida | A. Ismaila | D. Moher | R. Chou | D. Atkins | E. Whitlock | N. Aronson | David H. Smith
[1] N. Dreyer,et al. Registries for Evaluating Patient Outcomes: A User’s Guide , 2010 .
[2] R. Rosenthal,et al. Selective publication of antidepressant trials and its influence on apparent efficacy. , 2008, The New England journal of medicine.
[3] P. Santaguida,et al. The development of the McHarm quality assessment scale for adverse events , 2008 .
[4] S. Pocock,et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. , 2007, Preventive medicine.
[5] S. Pocock,et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies , 2007, The Lancet.
[6] S. Pocock,et al. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): Explanation and Elaboration , 2007, PLoS medicine.
[7] Kathleen N Lohr,et al. Emerging Methods in Comparative Effectiveness and Safety: Symposium Overview and Summary , 2007, Medical care.
[8] Andrew Herxheimer,et al. Systematic reviews of adverse effects: framework for a structured approach , 2007, BMC medical research methodology.
[9] Til Stürmer,et al. Performance of propensity score calibration--a simulation study. , 2007, American journal of epidemiology.
[10] S. Goodman,et al. Reproducible Research: Moving toward Research the Public Can Really Trust , 2007, Annals of Internal Medicine.
[11] G. Guyatt,et al. Association between unreported outcomes and effect size estimates in Cochrane meta-analyses. , 2007, JAMA.
[12] R. Chou,et al. Methodological shortcomings predicted lower harm estimates in one of two sets of studies of clinical interventions. , 2007, Journal of clinical epidemiology.
[13] Roger Chou,et al. Initial highly-active antiretroviral therapy with a protease inhibitor versus a non-nucleoside reverse transcriptase inhibitor: discrepancies between direct and indirect meta-analyses , 2006, The Lancet.
[14] E. Ding,et al. Adverse effects of cyclooxygenase 2 inhibitors on renal and arrhythmia events: meta-analysis of randomized trials. , 2006, JAMA.
[15] J. Emberson,et al. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials , 2006, BMJ : British Medical Journal.
[16] Paul M Ridker,et al. Reported outcomes in major cardiovascular clinical trials funded by for-profit and not-for-profit organizations: 2000-2005. , 2006, JAMA.
[17] P. Armstrong,et al. Transition from meeting abstract to full-length journal article for randomized controlled trials. , 2006, JAMA.
[18] John P.A. Ioannidis,et al. Comparison of evidence on harms of medical interventions in randomized and nonrandomized studies , 2006, Canadian Medical Association Journal.
[19] B. Giraudeau,et al. Reporting of drug tolerance in randomized clinical trials: when data conflict with authors' conclusions. , 2006, Annals of internal medicine.
[20] A. Avins,et al. Brief Communication: Better Ways To Question Patients about Adverse Medical Events , 2006, Annals of Internal Medicine.
[21] J. Aronson,et al. Case reports of suspected adverse drug reactions—systematic literature survey of follow-up , 2006, BMJ : British Medical Journal.
[22] Douglas G Altman,et al. Reporting of noninferiority and equivalence randomized trials: an extension of the CONSORT statement. , 2006, JAMA.
[23] Matthew H Samore,et al. The Research on Adverse Drug Events and Reports (RADAR) project. , 2005, JAMA.
[24] J. Grauer,et al. Industry Support and Correlation to Study Outcome for Papers Published in Spine , 2005, Spine.
[25] S. Normand,et al. Reader's guide to critical appraisal of cohort studies: 1. Role and design , 2005, BMJ : British Medical Journal.
[26] J. Avorn,et al. A review of uses of health care utilization databases for epidemiologic research on therapeutics. , 2005, Journal of clinical epidemiology.
[27] R Garside,et al. Do the findings of case series studies vary significantly according to methodological characteristics? , 2005, Health technology assessment.
[28] M. Egger,et al. Risk of cardiovascular events and rofecoxib: cumulative meta-analysis , 2004, The Lancet.
[29] B. Strom. Potential for conflict of interest in the evaluation of suspected adverse drug reactions: a counterpoint. , 2004, JAMA.
[30] B. Psaty,et al. Potential for conflict of interest in the evaluation of suspected adverse drug reactions: use of cerivastatin and risk of rhabdomyolysis. , 2004, JAMA.
[31] J. Ioannidis,et al. Better Reporting of Harms in Randomized Trials: An Extension of the CONSORT Statement , 2004, Annals of Internal Medicine.
[32] Anne-Marie Bagnall,et al. Bmc Medical Research Methodology Open Access Assessing Harmful Effects in Systematic Reviews , 2022 .
[33] J. Vandenbroucke. Benefits and harms of drug treatments , 2004, BMJ : British Medical Journal.
[34] M. McDonagh,et al. Hyperbaric oxygen therapy for traumatic brain injury: a systematic review of the evidence. , 2004, Archives of physical medicine and rehabilitation.
[35] Bruce M Psaty,et al. Detection, verification, and quantification of adverse drug reactions , 2004, BMJ : British Medical Journal.
[36] G. Guyatt,et al. Grading quality of evidence and strength of recommendations , 2004, BMJ : British Medical Journal.
[37] A. Hrõbjartsson,et al. Empirical evidence for selective reporting of outcomes in randomized trials: comparison of protocols to published articles. , 2004, JAMA.
[38] Jan P Vandenbroucke,et al. When are observational studies as credible as randomised trials? , 2004, The Lancet.
[39] J. Aronson,et al. A comparison of three different sources of data in assessing the frequencies of adverse reactions to amiodarone. , 2004, British journal of clinical pharmacology.
[40] Peter Fonagy,et al. Selective serotonin reuptake inhibitors in childhood depression: systematic review of published versus unpublished data , 2004, The Lancet.
[41] D. Spiegelhalter,et al. Systematic qualitative review of the literature on data monitoring committees for randomized controlled trials , 2004, Clinical trials.
[42] R. Leone,et al. Upper Gastrointestinal Bleeding Associated with the Use of NSAIDs Newer Versus Older Agents , 2004 .
[43] R. Leone,et al. Upper Gastrointestinal Bleeding Associated with the Use of NSAIDs , 2004, Drug safety.
[44] T. Carey,et al. A Critical Guide to Case Series Reports , 2003, Spine.
[45] Jeffrey K Aronson,et al. Anecdotes as evidence , 2003, BMJ : British Medical Journal.
[46] Douglas G Altman,et al. Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses , 2003, BMJ : British Medical Journal.
[47] Cancer Therapy Evaluation Program. Common Terminology Criteria for Adverse Events v3.0 (CTCAE) , 2003 .
[48] J. Sterne,et al. How important are comprehensive literature searches and the assessment of trial quality in systematic reviews? Empirical study. , 2003, Health technology assessment.
[49] D. Beek,et al. Dexamethasone in adults with bacterial meningitis , 2002 .
[50] Robert C. G. Martin,et al. Quality of Complication Reporting in the Surgical Literature , 2002, Annals of surgery.
[51] P. Shekelle,et al. A metaanalysis of severe upper gastrointestinal complications of nonsteroidal antiinflammatory drugs. , 2002, The Journal of rheumatology.
[52] N McKoy,et al. Systems to rate the strength of scientific evidence. , 2002, Evidence report/technology assessment.
[53] Jeffrey K Aronson,et al. Adverse drug reactions: keeping up to date , 2002, Fundamental & clinical pharmacology.
[54] G. K. Chambers,et al. Reporting of 6-month vs 12-month data in a clinical trial of celecoxib. , 2001, JAMA.
[55] Sheena Derry,et al. BMC Clinical Pharmacology BioMed Central BMC 1 2001, Clinical Pharmacology , 2001 .
[56] Jonathan A C Sterne,et al. Systematic reviews in health care: Investigating and dealing with publication and other biases in meta-analysis. , 2001, BMJ.
[57] J. Ioannidis,et al. Completeness of safety reporting in randomized trials: an evaluation of 7 medical areas. , 2001, JAMA.
[58] R Day,et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. , 2000, The New England journal of medicine.
[59] I. Edwards,et al. Adverse drug reactions: definitions, diagnosis, and management , 2000, The Lancet.
[60] R. Makuch,et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. , 2000, JAMA.
[61] M. Egger,et al. The hazards of scoring the quality of clinical trials for meta-analysis. , 1999, JAMA.
[62] B. Psaty,et al. Assessment and Control for Confounding by Indication in Observational Studies , 1999, Journal of the American Geriatrics Society.
[63] D. Cook,et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses? , 1998, The Lancet.
[64] J. Ioannidis,et al. Quantitative Synthesis in Systematic Reviews , 1997, Annals of Internal Medicine.
[65] J. Olié,et al. 68-4 Risk/benefit ratio , 1997, Biological Psychiatry.
[66] S D Walter,et al. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. , 1997, Journal of clinical epidemiology.
[67] J. Ware,et al. Equivalence trials. , 1997, The New England journal of medicine.
[68] J. Slattery,et al. A systematic review of the risks of stroke and death due to endarterectomy for symptomatic carotid stenosis. , 1996, Stroke.
[69] B Begaud,et al. False-positives in spontaneous reporting: should we worry about them? , 1994, British journal of clinical pharmacology.
[70] S. Goodman,et al. The Use of Predicted Confidence Intervals When Planning Experiments and the Misuse of Power When Interpreting Results , 1994, Annals of Internal Medicine.
[71] G. Danan,et al. Causality assessment of adverse reactions to drugs--I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. , 1993, Journal of clinical epidemiology.
[72] P. Easterbrook,et al. Publication bias in clinical research , 1991, The Lancet.
[73] L. Knodel,et al. Comparison of three algorithms used to evaluate adverse drug reactions. , 1986, American journal of hospital pharmacy.
[74] H. Morgenstern,et al. Epidemiologic Research: Principles and Quantitative Methods. , 1983 .
[75] G. Venning. Validity of anecdotal reports of suspected adverse drug reactions: the problem of false alarms , 1982, British medical journal.
[76] D. Rubin. Estimating causal effects of treatments in randomized and nonrandomized studies. , 1974 .
[77] M. Graffar. [Modern epidemiology]. , 1971, Bruxelles medical.